Loading...
NPI 1215302245 · Draper, UT · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Beechtree Diagnostics LLP is a clinical medical laboratory provider located in Draper, Utah. This profile covers 4 Medicare and 38 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Beechtree Diagnostics LLP |
| Address | 12351 S Gateway Park Pl Ste D-700 |
| City | Draper |
| State | UT |
| ZIP | 84020 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 2, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $34.7M |
| Medicare | $1M |
BEECHTREE DIAGNOSTICS LLP appears to operate primarily as a high-volume clinical drug testing laboratory: its top Medicare and Medicaid revenue-driving codes (G0483, G0480, G0481 and 80307) are all definitive or presumptive drug testing services, indicating the business is focused on toxicology and multi-drug panels rather than general anatomic pathology or routine chemistry testing. The code mix — heavy on definitive mass-spectrometry–level tests (G0483/G0480/G0481) plus instrumented screens (80307) — suggests a lab model serving behavioral health, substance-use monitoring, or large institutional testing programs.
Medicaid dominates this provider’s lifetime public-payer receipts: total Medicare revenue is $1M versus total Medicaid revenue of $34.7M, meaning the practice is effectively Medicaid-driven in scale and dependent on state payer volume for overall financial footprint. Analysts should treat this entity as primarily a Medicaid-billed service provider when evaluating contracting or network impact.
Revenue concentration is extreme within each payer but differs in scale: precomputed metrics show the top 3 Medicare codes account for 98.5% of Medicare revenue, and the top 3 Medicaid codes account for 88.2% of Medicaid revenue. This high concentration around a few drug-testing codes indicates the business has limited service diversification in its Medicare and Medicaid billing streams and therefore is sensitive to rate or policy changes affecting those specific CPT/HCPCS codes.
Competitive standing differs sharply between payers: nationally for Medicare, this provider’s volumes for G0483, 80307 and G0480 are described as typical or unremarkable (G0483 ranks #32/1063 providers, 97th percentile; 80307 ranks #64/4760, 99th percentile; G0480 ranks #89/1590, 94th percentile), indicating it is a solid but not dominant national participant for those Medicare codes. By contrast, in the Utah Medicaid market BEECHTREE is the clear leading lab for multiple high-revenue codes — G0483, 80307, and G0480 each rank #1 in-state with 100th-percentile or extreme-outlier language — signaling market dominance in Medicaid drug-testing volume within the state.
Several Medicaid codes are flagged as extreme outliers or notably above typical state volume: 80307 (280.4K claims, $6.2M, described as "extreme outlier, far above typical state volume") and G0480/G0483 (each rank #1 in-state) point to concentrated workflows and large recurring testing volumes tied to Medicaid beneficiaries or state-contracted programs. These descriptions suggest operational capacity for very large sample throughput in the state Medicaid channel compared with peers.
Average paid-per-claim patterns differ markedly between payers and codes: on Medicare, G0483 average paid/claim is $240 and G0480 is $112, while on Medicaid G0483 average paid/claim is $150 and G0480 is $81, reflecting lower per-claim Medicaid payments combined with much higher claim counts on Medicaid (e.g., G0483 at 140.9K claims Medicaid vs 2.9K claims Medicare). This combination of lower unit price and much larger Medicaid volume drives the provider’s Medicaid-dominant revenue picture.
Tenure is established but not long-standing by national laboratory incumbency standards: the NPI was enumerated on 2015-12-02 (~11 years ago), indicating the entity has had roughly a decade to scale operations and capture market share, particularly in Utah Medicaid where it now ranks at or near the top for key drug-testing codes. This tenure is consistent with an organization that has grown into a high-volume state-focused lab within that timeframe.
Given the concentration in a narrow set of drug-testing codes and the provider’s dominant in-state Medicaid position, business risk is concentrated around coverage, coding, and reimbursement changes to those specific CPT/HCPCS codes. Any contractual or policy shifts affecting G0483, 80307, G0480, or G0481 would likely have outsized revenue impact because the top three Medicaid codes already account for 88.2% of Medicaid revenue and the top three Medicare codes account for 98.5% of Medicare revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,910 | $240 | $697.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,540 | $60 | $215.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,090 | $110 | $121.5K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 100 | $150 | $15.5K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
38 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 140,890 | $150 | $21.1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 280,400 | $20 | $6.2M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 43,860 | $70 | $3.2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 33,220 | $80 | $2.7M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9,120 | $150 | $1.4M |
| 80177 | A lab tests a patient's specimen to determine the level of levetiracetam. | 23,000 | $0 | $0 |
| 80323 | The lab analyst identifies and evaluates the level of alkaloid drugs in a patient specimen that are not specified elsewhere in CPT® by a different code from the class of alkaloids. | 1,040 | $0 | $0 |
| 80325 | The lab analyst measures the amount of or detects the presence of three or four amphetamines, a central nervous system stimulant in the patient specimen. | 990 | $0 | $0 |
| 80334 | The lab analyst measures the amount of or detects the presence of six or more serotonergic antidepressants, which are psychiatric medications, in a patient specimen. | 1,050 | $0 | $0 |
| 80337 | The lab analyst measures the amount of or detects the presence of six or more tricyclic and other cyclicals antidepressants, which are psychiatric medications, in a patient specimen. | 1,050 | $0 | $0 |
Showing 1–10 of 38
How this provider's Medicaid billing volume and revenue compare to other Utah providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Utah median
38 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 490 | $150 | $2.1M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 660 | $60 | $625K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 70 | 1,610 | $30 | $367.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 40 | 770 | $90 | $231.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 480 | $110 | $189.3K |
| 80349 | The lab analyst measures the amount of or detects the presence of natural cannabinoids in a patient specimen. | 2 | 10 | 1,050 | $10 | $8.9K |
| 80323 | The lab analyst identifies and evaluates the level of alkaloid drugs in a patient specimen that are not specified elsewhere in CPT® by a different code from the class of alkaloids. | 1 | 10 | 990 | $10 | $8.3K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 2 | 10 | 1,050 | $10 | $7.4K |
| 80365 | The lab analyst measures the amount of or detects the presence of oxycodone, a synthetic opioid pain medication, in a patient specimen. | 1 | 10 | 1,050 | $10 | $5.6K |
| 80177 | A lab tests a patient's specimen to determine the level of levetiracetam. | 1 | 10 | 480 | $1 | $5.5K |
Showing 1–10 of 38
Other providers in the same ZIP code as Beechtree Diagnostics LLP, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Utah Case Management | UT | Case Management Agency | $0 | $13.3M |
| Lone Peak Hospital, Inc. | UT | General Acute Care Hospital | $0 | $4.1M |
| After Hours Medical LLC | UT | Urgent Care Clinic/Center | $0 | $3.2M |
| Rocky Mountain Laboratories LLC | UT | Clinical Medical Laboratory | $224.5K | $2.1M |
| Utnv Draper Operator, LLC | UT | Assisted Living Facility | $0 | $2.2M |
| Beechtree Molecular Lab LLC | UT | Clinical Medical Laboratory | $236.8K | $862.7K |
| Draper City | UT | Ambulance | $115.3K | $978.1K |
| Spencer Hardenbrook | UT | Family Medicine Physician | $965.5K | $3.7K |
| Jeffrey Welch | UT | General Practice Dentistry | $0 | $856.8K |
| Utah Surgery Center LP | UT | Ambulatory Surgical Clinic/Center | $473.4K | $337.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.